of the MedPlus parent's free reserves are share premium, not profit
MedPlus's ₹130 crore buyback rests on share premium, not profit
MedPlus Health Services will buy back up to ₹130 crore of its own shares at no more than ₹750 each, says the board resolution it filed on 10 November 2026. So sellers get that price? Not quite: it is only a ceiling. And the size says more about the parent company's books than its profits.
MedPlus sells medicines and wellness products in its stores and online, and runs diagnostic labs. In this buyback its broker buys on the stock exchange at the market price, day by day, while that is under the cap, which is 22.09% above the average price of the month before the board took it up. The 17,33,333 shares in the notice are just what the full amount buys at the cap, and MedPlus need spend only ₹97.5 crore, or 75% of it.
Why that size? A board can approve a buyback alone only up to 10% of paid-up capital and free reserves, on the parent's or the group's accounts, whichever is lower. Above that, shareholders vote. MedPlus's board took 98.7% of that limit.
The parent's March 2026 accounts set it. Share premium, money investors paid above the shares' face value, made up 97% of its free reserves. Its retained profit was ₹1.5 crore, against ₹651.6 crore for the group, whose subsidiaries do most of the selling: the parent booked 12.8% of group revenue from April to September.
The parent can pay, with ₹207 crore in cash, bank deposits and fund investments on 30 September. Promoters cannot sell into the buyback, so their stake rises from 40.19% to 40.78% if every share at the cap is bought.
So the headline price is the most MedPlus will pay, not what sellers will get. And on paper the buyback mostly hands investors back their own premium, because the group's profits sit a level below the company doing the buying.
MedPlus must spend only ₹97.5 crore of its ₹130 crore buyback
What the November 2026 open market buyback must spend, in ₹ crore. A quarter of the headline size is optional.
₹ CRORE
- Must spend in the first half of the window52.0 40.0%
- Must spend by the end45.5 35.0%
- May spend, but need not32.5 25.0%
Shares are bought on the exchange at market prices up to ₹750 each; 17,33,333 shares at that price.
MedPlus Health Services, BSE filing of 10 November 2026: board resolution and public announcement for the buyback · 13 Nov 2026 to 16 Feb 2027
MedPlus's parent set the buyback limit, not the group
MedPlus's accounts at 31 March 2026, the parent company alone and the whole group, in ₹ crore. The lower, the parent's, caps a buyback the board can approve without a shareholder vote.
₹ CRORE
Parent company aloneWhole group
The board approved ₹130 crore, 98.7% of this limit
The limit is 10% of paid-up capital and free reserves, on whichever accounts give the lower figure. Above it, shareholders must vote.
MedPlus Health Services, BSE filing of 10 November 2026: public announcement for the buyback, section 6 · 31 Mar 2026
97% of MedPlus's parent reserves are share premium
The MedPlus parent company's free reserves at 31 March 2026, in ₹ crore. Retained profit is a sliver.
₹ CRORE
- Retained profit1.5 0.12%
- Share premium1,255.4 97.1%
- General reserve36.3 2.8%
Share premium is money investors paid for shares above their ₹2 face value. The whole group's retained profit was ₹651.6 crore.
MedPlus Health Services, BSE filing of 10 November 2026: public announcement for the buyback, section 6, standalone · 31 Mar 2026
Sources
- MedPlus Health Services, BSE filing of 10 November 2026: board resolution of 6 November 2026 and public announcement for the open market buyback (PDF)
- MedPlus Health Services, BSE filing of 27 October 2026: unaudited standalone and consolidated results for the quarter and half year to 30 September 2026 (PDF)